key: cord-1030743-5s30ihv3
authors: Salg, G. A.; Ganten, M. K.; Baumhauer, M.; Heussel, C. P.; Kleesiek, J.
title: A globally available COVID-19 - Template for clinical imaging studies
date: 2020-04-07
journal: nan
DOI: 10.1101/2020.04.02.20048793
sha: aa8f0d5f6f19e863aaf392554c83d93d4426ea26
doc_id: 1030743
cord_uid: 5s30ihv3

Background The pandemic spread of COVID-19 has caused worldwide implications on societies and economies. Chest computed tomography (CT) has been found to support both, current diagnostic and disease monitoring. A joint approach to collect, analyze and share clinical and imaging information about COVID-19 in the highest quality possible is urgently needed. Methods An evidence-based reporting template was developed for assessing COVID-19 pneumonia using an FDA-approved medical software. The annotation of qualitative and quantitative findings including radiomics features is performed directly on primary imaging data. For data collection, secondary information from the patient history and clinical data such as symptoms and comorbidities are queried. Results License-royalty free, cloud-based web platform and on-premise deployments are offered. Hospitals can upload, assess, report and if pseudonymized share their COVID-19 cases. The aggregation of radiomics in correlation with rt-PCR, patient history, clinical and radiological findings, systematically documented in a single database, will lead to optimized diagnosis, risk stratification and response evaluation. A customizable analytics dashboard allows the explorative real-time data analysis of imaging features and clinical information. Conclusions The COVID-19-Template is based on a systematic, computer-assisted and context-guided approach to collect, analyze and share data. Epidemiological and clinical studies for therapies and vaccine candidates can be implemented in compliance with high data quality, integrity and traceability.

The infection with SARS-CoV-2 has become pandemic since the first cases have been reported from 49 the Hubei province to the WHO on Dec. 31 st , 2019. This led to a global health crisis with impacts for 50 each individual patient infected with COVID-19, societies and economies.

Dynamic movement patterns, high contagiousness in combination with an estimated substantial 52 asymptomatic and undocumented proportion of infected people 1 enables a fast spread of the infection 53 and might only be slowed down by drastic disease containment efforts while vaccination and therapy 54 are lacking. [2] [3] [4] The current situation in Italy and other parts of Europe proves that the previous 55 measures for disease control did not suffice and that even countries with a strong health care 56 infrastructure are not adequately staffed with critical care resources. Its current spread in low income 57 countries or those with weak healthcare systems is to be feared.

Besides more aggressive containment, more efforts towards an evidence-based clinical diagnosis, 59 treatment and monitoring including the utilization of new technologies and artificial intelligence are 60 to be strived for. 5 The global spread of COVID-19 demands a global response across national borders.

We perceive an urgent need for systematic data collection, comprising imaging data and analysis, of 62 patients suffering from COVID-19 pneumonia. Therefore, we wish to initiate an open-access platform 63 for data collection using commonly developed criteria for multi-modal diagnostics, staging and 64 monitoring of the disease. This will serve as a mandatory foundation for swiftly conducting future 65 clinical trials aiming at investigating novel diagnostic and therapeutic options.

At present, real-time polymerase chain reaction (rt-PCR) is commonly used for diagnosis of COVID-19.

This method, however, requires sophisticated lab technology and material with limited availability.

Until now, the results are available earliest the next day. Meanwhile, the patient has to be treated as 70 potentially COVID-19 positive, requiring costly isolation for safety of staff and eventually cohort 71 isolation with a risk to get infected therein. While this method detects the virus, it does not provide 72 quantitative data on the extent or stage of the disease. Fang et al. claimed that the sensitivity of rt-73 PCR at +3/-3 days after the appearance of external symptoms is only 71%. 6 The study also found that 74 in 98% of patients at the same stage, abnormalities that are characteristic of viral pneumonia are 75 visible in computed tomography (CT) of the lungs. 6 The correlation of COVID-19 infection with features 76 in chest CT has been confirmed by other studies. 7 A sensitivity of 91.9% for a combination of a chest 77 CT and rt-PCR test, compared to 78.2% for a single rt-PCR alone or 86.2% for two subsequent rt-PCR 78 tests was found. 7 Researchers from China and the Netherlands examined data from 1,014 patients and 79 concluded that CT imaging has high sensitivity for diagnosis of COVID-19 and furthermore offers the show preference for middle-aged to elderly individuals with comorbidities, 11 the imaging information 91 could be combined with other patient characteristics to predict the prognosis of patients, so as to 92 identify those requiring intensive medical care. 12,13 Early stages of COVID-19 pneumonias mainly 93 involve pure GGOs evolving to multiple GGOs with consolidations in lesions and crazy-paving pattern 94 in a progressive stage. 14,15 This disease monitoring by chest CT imaging has already been used in studies 95 to determine treatment regimens of patients. 11 We conjecture that the aggregation of radiomics 96 features in correlation with rt-PCR, patient history, clinical and radiological findings, systematically 97 All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org /10.1101 /10. /2020 The parameters for systematic data collection were determined based on the current evidence [last radiological findings that might contribute to diagnosis or monitoring of COVID-19 or might be of prognostic value for the course of the disease are included in the developed electronic case report form (eCRF). As comorbidities have been described as a variable with prognostic value, study data for 106 comorbidities such as hypertension [10] [11] [12] [13] [16] [17] [18] , cardiovascular diseases [10] [11] [12] [13] 16, 17, 19, 20 , chronic obstructive 107 lung disease and other respiratory system diseases [10] [11] [12] [13] 16, 17, 19, 20 , diabetes [10] [11] [12] [13] [16] [17] [18] 20 and malignant 108 diseases [10] [11] [12] [13] 17, 19, 20 have been pooled (Figure 1 , left). Clinical symptoms include fever, 10-13,15-21 cough, 10-109 13,15-21 expectorations, [10] [11] [12] [13] [15] [16] [17] [18] [19] 21 hemoptysis, 10, 11, 16, 18 dyspnea, [10] [11] [12] [13] 15, 16, [19] [20] [21] 

1122/1294), 10, 16, 17, 19 typically with bilateral lung involvement, 10,11,17,18 peripheral distribution 16,17,19,21 113 and ground-glass opacification of the lesions 10, [16] [17] [18] [19] 21 . Depending on the stage of the disease 114 consolidations 16-19,21 , intra-18,21 and interlobular 16-18,21 septal thickening, crazy paving pattern, [16] [17] [18] 115 spider web signs 16,18 and air bronchogram sign 17,19,21 were observed (Figure 1 , right). In contrast, pleural 116 effusion 16-19,21 and lymphadenopathy [16] [17] [18] [19] 21 were found rarely and do not seem to be typical for COVID-117 19 pneumonia. Although current evidence for COVID-19 pneumonia relies on data from preliminary 118 clinical studies and thus is most likely subjected to change over time, we illustrated that some clinical 119 symptoms and radiological findings were found more frequently than others, supporting a diagnosis 120 of COVID-19 pneumonia, whereas others seem to be very rare and support a consideration of other 121 differential diagnoses (Figure 1) . Nevertheless, or precisely because of it, these parameters were 122 included in the eCRF to enable a solid decision-making.

An approach for unified data collection and analysis using comparable criteria

Our proposal emphasizes the importance of quality, integrity and traceability of data to allow for later 125 epidemiological analysis and application of artificial intelligence algorithms. We wish to establish an 126 optimized digital signature of the disease consisting of imaging biomarkers, patient history and other 127 clinical follow-up data obtained in a reproducible matter. We demonstrate, that such a standardized 128 diagnostic procedure can be easily and globally implemented. The proposed template or eCRF, 129 respectively does not only provide a structured method for evaluating the pulmonary involvement but All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org /10.1101 /10. /2020 is also essential for quantitative assessment of the progression of the disease in clinical trials beginning 131 in the near future. A standardized assessment is only possible if the imaging findings are quantitatively 132 collected and evaluated on a supra-regional, preferably global level using comparable criteria. A 133 representative assessment of COVID-19 pneumonia will be enabled by using the collected annotated 134 data consisting of primary imaging data and secondary clinical data. These provide structured primary 135 data that can be universally shared and analyzed. Therefore, an electronic case report form was 136 developed on the basis of the mint lesion TM medical software product platform (Mint Medical GmbH,

Heidelberg, Germany) (Figure 2, 3) .

The template is available free of charge and has already been deployed to university hospitals and 139 health care providers in 8 countries around the world, including severely affected regions of the United 140 Figure 2 : System. architecture cloud-based web platform. Every health care center has the possibility upload anonymized data to the web platform and use the eCRF based on the mint lesion medical product software package. Figure 3 : COVID-19 electronic case report form on mint lesion TM software platform. Here: Exemplary patient with confirmed COVID-19 pneumonia and chest CT at two subsequent time points. The patient was assessed and evaluated using the eCRF by an experienced radiologist. The assessment and evaluation are performed directly on primary imaging data and automatic rule-based evaluation of the disease progression. The patient was included in a clinical trial directly without the necessity of further data collection or twofold data documentation.

All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org /10.1101 /10. /2020 based web platform will be provided, where every other hospital and health care center may have free 142 access and can upload, assess, report and document their cases (Figure 2 , full exemplary report s. 

The particular strength of the developed eCRF lies in the fact that any imaging-based value is 175 immediately linked to its context, e.g. anatomical location, but also further related data of clinical 176 significance. Due to the integration in the mint lesion software platform minable data is obtained in a 177 semantic data model with a HIPAA-and FDA CFR Part 11-ready audit trail, immediately applicable for 178 Phase I-III clinical trials and other medical research. Furthermore, data is exportable in various human- Figure 4 : Overview of locations of major findings in chest CT. Longitudinal overview of documented findings in chest CT examination (here: evaluation after second chest CT in COVID-19 disease course). Recession of the size (LA: long axis, SA: short axis) of the imaging findings. These findings are included in an automatically generated case report file for COVID-19 positive patient and study data repository.

All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org /10.1101 /10. /2020 and machine-readable data formats for external analysis. All image annotations can be exchanged in 180 open formats, like NRRD, or as DICOM-compliant annotations (DICOM RT, DICOM Seg. Surface Obj.).

The proposed solution supports the detection and standardized recording of clinical and radiological 186 disease features consistent with the course of COVID-19 infection as well as the relevant 187 epidemiological disease history. We envisage that this data-driven approach will be used in current 

Our approach has limitations. Data acquisition and handling of an eCRF is more time consuming than 213 a reading in clinical routine. Further, integral data acquisition of imaging and clinical parameters 214 requires an interdisciplinary input, which might not be available for every case. Currently, the template 215 is designed for CT imaging only, but providing an eCRF for Chest-X-rays can be realized easily and is the 216 scope for future work. Lastly, it might also appear controversial, that an increased research effort is 217 encouraged even though manpower is limited during the current pandemic. The primary goal is to 218 provide a tool for future clinical studies which are urgently needed.

We do not want to present a predefined global standard for the assessment and reporting for patients 220 with COVID-19 infection, instead the intention is to initiate an evidence-based approach to define a 221 joint global standard that can be adapted to the dynamic situations and discoveries yet to come. This 222 might also discover regional difference in the disease leading to a personalized patient management.

The eCRF can be adapted and refined according to evidence generated in ongoing and future clinical 224 trials but also through the crowd-intelligence approach itself. Any addition or changes in template 225 parameters will not put previously collected data in danger. Data integrity is permanently ensured, 226 and even retrospective acquisition of certain parameters will be possible if applicable.

Chest CT as a supporting tool for diagnosis and furthermore therapy monitoring has distinct benefits 228 such as short turnaround time of the CT, wide availability of the equipment and the possibility of 229 assessing the stage of the disease including response to therapeutic measures. However, it needs to 230 be emphasized that even though the reporting is conducted directly on the CT image data, the eCRF 231 All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org /10.1101 /10. /2020 With the presented systematic, computer-assisted and context-guided approach to capture data and 240 annotations based on an easy-to-use software free of charge, we wish to contribute to a joint global 241 response against the COVID-19 pandemic in a balancing act between research and clinical routine and 242 further to initiate a change of clinical study culture. 

Substantial undocumented infection facilitates the rapid dissemination 257 of novel coronavirus (SARS-CoV2)

Clinical characteristics of 24 asymptomatic infections with COVID-19 259 screened among close contacts in Nanjing

Feasibility of controlling COVID-19 outbreaks by isolation 261 of cases and contacts

Asymptomatic carrier state, acute respiratory disease

COVID-19: towards controlling of a pandemic

Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR

Application and optimization of RT-PCR in diagnosis of 270 SARS-CoV-2 infection

Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 272 2019 (COVID-19) in China: A Report of 1014 Cases

Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl 276

Clinical characteristics of novel coronavirus cases in tertiary 12

Clinical features of patients infected with 2019 novel coronavirus 14

Novel Coronavirus (COVID-19) Pneumonia: Serial Computed 284

CT Imaging and Differential Diagnosis of COVID-19

Chest CT Findings in Patients with Corona Virus Disease 2019 and 288 its Relationship with Clinical Features

Imaging and clinical features of patients with 2019 novel coronavirus 290 SARS-CoV-2

Initial clinical features of suspected Coronavirus 292 Disease 2019 in two emergency departments outside of Hubei

Clinical characteristics and imaging manifestations of the 2019 294 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city

Epidemiological and clinical characteristics of 99 cases of 2019 297 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical and computed tomographic imaging features of novel